Avadel Pharmaceuticals plc (AVDL)
21.64
+0.01 (0.05%)
Inactive · Last trade price on Feb 11, 2026
Avadel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 248.52 | 169.12 | 27.96 | - | - | 22.33 | |
Revenue Growth (YoY) | 79.88% | 504.79% | - | - | - | -62.28% |
Cost of Revenue | 12.64 | 15.28 | 0.85 | - | - | 5.74 |
Gross Profit | 235.88 | 153.84 | 27.12 | - | - | 16.59 |
Selling, General & Admin | 191.46 | 181.04 | 151.71 | 74.52 | 68.5 | 32.41 |
Depreciation & Amortization Expenses | - | - | - | - | - | 0.41 |
Research & Development | 39.89 | 15.2 | 13.26 | 20.7 | 17.1 | 20.44 |
Other Operating Expenses | - | - | - | 3.35 | -0.05 | 49.04 |
Total Operating Expenses | 231.36 | 196.24 | 164.97 | 98.56 | 85.55 | 102.3 |
Operating Income | 4.52 | -42.4 | -137.85 | -98.56 | -85.55 | 5.82 |
Interest Income | 1.93 | 4.15 | 0.09 | -0.54 | 2.34 | -0.83 |
Interest Expense | -9.71 | -10.83 | -9.89 | -12.34 | -9.94 | -12.99 |
Other Non-Operating Income (Expense) | - | - | -13.13 | - | - | 2.93 |
Total Non-Operating Income (Expense) | -7.78 | -6.68 | -22.93 | -12.88 | -7.6 | -10.9 |
Pretax Income | -3.26 | -49.08 | -160.78 | -111.44 | -93.15 | -5.08 |
Provision for Income Taxes | - | -0.25 | -0.5 | 26.03 | -15.82 | -12.11 |
Net Income | -0.28 | -48.83 | -160.28 | -137.46 | -77.33 | 7.03 |
Net Income to Common | -0.28 | -48.83 | -160.28 | -137.46 | -77.33 | 7.03 |
Shares Outstanding (Basic) | 97 | 95 | 80 | 60 | 59 | 53 |
Shares Outstanding (Diluted) | 98 | 95 | 80 | 60 | 59 | 55 |
Shares Change (YoY) | 5.19% | 18.67% | 33.41% | 2.66% | 6.54% | 46.89% |
EPS (Basic) | -0.00 | -0.51 | -2.00 | -2.29 | -1.32 | 0.13 |
EPS (Diluted) | -0.00 | -0.51 | -2.00 | -2.29 | -1.32 | 0.13 |
Free Cash Flow | 34.54 | -46.91 | -128.51 | -71.02 | -77.34 | -48.83 |
Free Cash Flow Per Share | 0.35 | -0.49 | -1.60 | -1.18 | -1.32 | -0.89 |
Gross Margin | 94.91% | 90.97% | 96.97% | - | - | 74.29% |
Operating Margin | 1.82% | -25.07% | -492.97% | - | - | 26.04% |
Profit Margin | -0.11% | -28.87% | -573.17% | - | - | 31.47% |
FCF Margin | 13.90% | -27.74% | -459.58% | - | - | -218.64% |
EBITDA | 8.2 | -39.72 | -136.08 | -97.07 | -84.73 | 7.51 |
EBITDA Margin | 3.30% | -23.49% | -486.65% | - | - | 33.60% |
EBIT | 4.52 | -42.4 | -137.85 | -98.56 | -85.55 | 5.82 |
EBIT Margin | 1.82% | -25.07% | -492.97% | - | - | 26.04% |
Effective Tax Rate | - | 0.50% | 0.31% | -23.35% | 16.98% | 238.29% |